We used the Nucleic Acid Linked Immuno‐Sandwich Assay (NULISA) central nervous system panel for biomarker quantification in plasma, serum, and cerebrospinal fluid of patients with AD, mild cognitive impairment, Lewy body dementia, progranulin (GRN) mutation carriers. This evidence concerns the gene GRN and Cognitive impairment.